期刊
ONCOLOGIST
卷 15, 期 -, 页码 34-41出版社
WILEY
DOI: 10.1634/theoncologist.2010-S4-34
关键词
Hepatocellular carcinoma; Liver transplantation; Ablation techniques; Operative surgical procedure
类别
资金
- Biosphere Medical
- Biocompatibles
- Genentech
- Bayer HealthCare
- Philips Medical
- Context Vision
- Gideon
- RSNA
- Bayer
- Bayer HealthCare Pharmaceuticals
For patients with early-stage hepatocellular carcinoma (HCC), potentially curative treatment options exist, including liver transplantation, surgical resection, and ablation therapy. These treatments are associated with survival benefits, and outcomes are optimized by identification of appropriate patients. However, further studies are needed to definitively confirm optimal treatment approaches for all patients. Treatment patterns vary in different parts of the world as a result of geographic differences in the incidence and presentation of the disease. In particular, because of successful screening programs, a high proportion of tumors that are identified in Japan are amenable to curative treatments, which are appropriate smaller proportion of patients in the west, although screening is now widely carried out in industrialized countries. Differences in the applicability of transplantation are also evident between the west and Asia. Although existing treatments for early-stage HCC are supported by considerable evidence, there remain significant data gaps. For example, further data, ideally from randomized controlled trials, are needed regarding: the use of neoadjuvant and adjuvant therapy to decrease the rate of recurrence after resection or ablation, further investigation of the role of chemoprevention following resection, and prospective analysis of outcomes of living donor compared with deceased donor liver transplantation. The Oncologist 2010; 15(suppl 4): 34-41
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据